About the CRISPR/Cas9 Gene Editing Patent
Shareholders of biotechnology firms specialized in CRISPR gene editing technology are in a state of confusion regarding the technology's patents. The confusion is caused by the U.S. Patent and Trademark Office (USPTO) decision to sustain the intellectual property awarded to the Broad Institute of MIT and Harvard. This ruling has caused the stock of the firm Editas (EDIT), which licensed the technology from Broad Institute and Harvard to rally, while the other firms, including Intellia Therapeutics (NTLA) and CRISPR Therapeutics (CRSP), which license . . .